Agios Pharmaceuticals Dirección

Dirección controles de criterios 2/4

El CEO de Agios Pharmaceuticals' es Brian Goff , nombrado en Aug 2022, tiene una permanencia de 1.58 años. compensación anual total es $12.21M, compuesta por 2.5% salario y 97.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.096% de las acciones de la empresa, por valor de MX$26.90M. La antigüedad media del equipo directivo y de la junta directiva es de 2.5 años y 8.4 años, respectivamente.

Información clave

Brian Goff

Chief Executive Officer (CEO)

US$12.2m

Compensación total

Porcentaje del salario del CEO	2.5%
Permanencia del CEO	1.6yrs
Participación del CEO	0.1%
Permanencia media de la dirección	2.5yrs
Promedio de permanencia en la Junta Directiva	8.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Brian Goff en comparación con los beneficios de Agios Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$352m
Sep 30 2023	n/a	n/a	-US$220m
Jun 30 2023	n/a	n/a	-US$210m
Mar 31 2023	n/a	n/a	-US$218m
Dec 31 2022	US$12m	US$308k	-US$232m

Compensación vs. Mercado: La compensación total de Brian($USD12.21M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD837.82K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Brian con los resultados de la empresa.

CEO

Brian Goff (54 yo)

1.6yrs

Permanencia

US$12,212,046

Compensación

Mr. Brian M. Goff, M.B.A. is Chief Executive Officer and Director at Agios Pharmaceuticals, Inc. from August 08, 2022. He had been Executive Vice President at Alexion Pharmaceuticals, Inc. since June 01, 2...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Brian Goff	CEO & Director	1.6yrs	US$12.21m	0.096% $ 26.9m
Cecilia Jones	Chief Financial Officer	1.5yrs	US$2.91m	0.026% $ 7.4m
James Burns	Corporate Secretary & Chief Legal Officer	no data	US$1.74m	0.066% $ 18.6m
Sarah Gheuens	Chief Medical Officer and Head of Research & Development	2.5yrs	US$1.85m	0.070% $ 19.5m
Lewis Cantley	Co-Founder & Member of Scientific Advisory Board	no data	US$333.51k	sin datos
Tak Mak	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Craig Thompson	Co-Founder & Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Shin-San Su	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
T. Washburn	Principal Accounting Officer	2.6yrs	sin datos	0.0051% $ 1.4m
Clive Patience	Chief Technical Operations Officer	6.8yrs	sin datos	sin datos
Christopher J. Taylor	Vice President of Investor Relations & Corporate Communications	no data	sin datos	sin datos
Steven Vickers	Vice President of Sales	no data	sin datos	sin datos

2.5yrs

Permanencia media

56.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AGIO * se considera experimentado (2.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Brian Goff	CEO & Director	1.6yrs	US$12.21m	0.096% $ 26.9m
Lewis Cantley	Co-Founder & Member of Scientific Advisory Board	no data	US$333.51k	sin datos
Tak Mak	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Craig Thompson	Co-Founder & Chairman of Scientific Advisory Board	no data	sin datos	sin datos
Shin-San Su	Co-Founder & Member of Scientific Advisory Board	no data	sin datos	sin datos
Jacqualyn Fouse	Chair of the Board of Directors	6.3yrs	US$5.26m	0.23% $ 64.7m
Marc Tessier-Lavigne	Member of Scientific Advisory Board	7.6yrs	US$302.85k	sin datos
Charles Sawyers	Member of Scientific Advisory Board	15.1yrs	sin datos	sin datos
Kaye Foster-Cheek	Lead Independent Director	9.3yrs	US$434.80k	0.014% $ 3.9m
David Schenkein	Independent Director	14.6yrs	US$432.30k	0.84% $ 236.5m
Matthew Vander Heiden	Member of Scientific Advisory Board	15.3yrs	sin datos	sin datos
Scott Biller	Member of Scientific Advisory Board	3.2yrs	US$3.21m	sin datos

8.4yrs

Permanencia media

66yo

Promedio de edad

Junta con experiencia: La junta directiva de AGIO * se considera experimentada (8.4 años de antigüedad promedio).

Agios Pharmaceuticals Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Agios Pharmaceuticals, Inc. Announces Board Changes

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Recent updates

Agios Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Agios Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 15, 2024

Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Agios Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Agios Pharmaceuticals, Inc. Announces Board Changes

Agios Pharmaceuticals, Inc. Presents Updated PYRUKYND® (mitapivat) Long-term Extension Data Demonstrating Sustained Clinical Benefits in Adults with Pyruvate Kinase (PK) Deficiency at 64th ASH Annual Meeting and Exposition

Agios Pharmaceuticals, Inc. Appoints Tsveta Milanova as Chief Commercial Officer, Effective Jan. 3, 2023

Agios Pharmaceutical's PYRUKYND® Approves in the EU for the Treatment of Pyruvate Kinase (PK) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Appoints Cecilia Jones as Chief Financial Officer, Effective September 26, 2022

Agios Pharmaceuticals, Inc. Receives Positive Chmp Opinion for Pyrukynd® (Mitapivat) for the Treatment of Pyruvate Kinase (Pk) Deficiency in Adult Patients

Agios Pharmaceuticals, Inc. Announces Resignation of Jonathan Biller as Chief Financial Officer, Effective September 16, 2022

Agios Pharmaceuticals, Inc. Appoints Rahul Ballal and Cynthia Smith to Board of Directors

Agios Pharmaceuticals, Inc. Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent a- and ß-Thalassemia

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces Management Changes, Effective August 8, 2022

Insufficient new directors

Agios Presents New Clinical Data Supporting the Benefits of Pyrukynd® Treatment in Adults with PK Deficiency At European Hematology Association Annual Congress

Agios Pharmaceuticals, Inc. Announces Resignation of Bruce Car as Chief Scientific Officer, effective as of August 1, 2022

Agios Pharmaceuticals, Inc. Announces Management Changes

Agios Pharmaceuticals, Inc. Announces Executive Changes

Agios Pharmaceuticals, Inc. Announces Resignation of Ian T. Clark from the Board

Agios Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

Agios Pharmaceuticals, Inc. Announces FDA Approval of Pyrukynd (Mitapivat) as First Disease-Modifying Therapy for Hemolytic Anemia in Adults with Pyruvate Kinase Deficiency

No longer forecast to breakeven

Insufficient new directors

No longer forecast to breakeven

Agios Pharmaceuticals, Inc. Presents Mitapivat Long-term Extension Data Demonstrating Durability of Hemoglobin Response and Transfusion Burden Reduction in Adults with Pyruvate Kinase (PK) Deficiency at 63rd ASH Annual Meeting and Exposition

Chief Commercial Officer Darrin Miles has left the company

Insufficient new directors

Forecast to breakeven in 2021

Forecast to breakeven in 2021

Agios Pharmaceuticals, Inc. Announces FDA Acceptance and Priority Review of New Drug Application for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Principal Accounting Officer and VP of Accounting, Treasury & Tax Carman Alenson has left the company

Agios Pharmaceuticals, Inc.(NasdaqGS:AGIO) dropped from Russell Midcap Value Index

Agios Pharmaceuticals, Inc. Submits New Drug Application to FDA for Mitapivat for Treatment of Adults with Pyruvate Kinase Deficiency

Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Study of Mitapivat in Non-Transfusion-Dependent a- and ß-Thalassemia at the European Hematology Association Virtual Congress

Agios Reports Clinical Data Presentations

Agios Pharmaceuticals, Inc. Announces Closing of Oncology Business Sale to Servier

Agios Submits Supplemental New Drug Application to FDA for TIBSOVO® (ivosidenib tablets) for Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Agios Pharmaceuticals, Inc. Announces the Appointment of Darrin Miles to Role of Chief Commercial Officer

Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma

Servier Pharmaceuticals, LLC entered into a definitive agreement to acquire oncology business from Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) for $2 billion.

Agios Pharmaceuticals, Inc. Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused

Agios Pharmaceuticals, Inc. Launches Anemia ID

Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease

Third quarter 2020 earnings released: US$1.43 loss per share

Revenue misses expectations

Agios Announces Withdrawal of European Marketing Authorization Application for TIBSOVO as a Treatment for Relapsed or Refractory IDH1-mutant Acute Myeloid Leukemia

Agios Pharmaceuticals, Inc. Announces Final Overall Survival Data from Phase 3 ClarIDHy Study of TIBSOVO

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad